[Expert consensus on the treatment of glioma with radioactive seeds].

Radioactive seeds brachytherapy for glioma has been available for more than half a century. Numerous studies have consistently supported that this therapy is minimally invasive, safe, and effective. Glioma has the potential to form a new treatment paradigm because of low incidence of hematogenous and lymphatic metastases. However, it is difficult to stress the importance of radioactive seeds therapy because of lacking in high-grade evidence achieved from multicenter, prospective, randomized controlled clinical studies. Slow progression in research is mainly due to the complexity of the cranial anatomy and neurological malignancies. Neurosurgeons, oncologists, interventionalists, or imaging physicians all have difficulties in performing radioactive seeds therapy for glioma surgery because technical plights are not overcome by single division. Therefore, to establish a standard and consensus on the treatment of glioma with radioactive seeds will assist in solving the problems and forming a relatively unified treatment procedure and standard, so that this technology can be applied and benefit glioma patients. The article focuses on the treatment standard and consensus related to the technology of radioactive seeds therapy for glioma, composing the basis of consensus formation, the physics basis of radioactive iodine-125 seeds therapy for glioma, clinical application and treatment process. 放射性粒子近距离治疗脑胶质瘤的应用已超半个世纪，大量研究得到一致结论，该疗法微创安全有效。脑胶质瘤因较少发生血行转移和淋巴转移，更具备形成新治疗模式的潜质，但是由于缺乏多中心、前瞻性、随机对照临床研究这样循证医学高级别的证据，难以确立放射性粒子治疗在脑胶质瘤综合治疗中的地位。研究缓慢的原因为颅脑结构的特殊性和神经系统肿瘤的复杂性，无论是神经外科、肿瘤科、介入科，还是影像科医师，单独完成放射性粒子治疗脑胶质瘤手术，均因遇到不同的技术瓶颈而难以开展。因此，建立放射性粒子治疗脑胶质瘤规范与共识，有利于解决该治疗方面的技术瓶颈，形成相对统一的治疗流程与规范，从而使该项技术得到更广泛的推广应用，使更多脑胶质瘤患者获益。本文主要基于放射性粒子治疗脑胶质瘤技术建立起治疗规范与共识，主要涵盖了共识形成的基础，放射性碘-125粒子治疗脑胶质瘤物理学基础、临床应用及治疗流程等。.